Sensus HealthcareSRTS
SRTS
About: Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Employees: 35
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
2,780% more call options, than puts
Call options by funds: $144K | Put options by funds: $5K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
27% more capital invested
Capital invested by funds: $17.7M [Q2] → $22.6M (+$4.85M) [Q3]
6% more funds holding
Funds holding: 47 [Q2] → 50 (+3) [Q3]
3.51% more ownership
Funds ownership: 20.19% [Q2] → 23.71% (+3.51%) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
55%
upside
Avg. target
$12.50
76%
upside
High target
$14
97%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target | 55%upside $11 | Buy Maintained | 18 Nov 2024 |
Maxim Group Anthony Vendetti 43% 1-year accuracy 6 / 14 met price target | 97%upside $14 | Buy Maintained | 15 Nov 2024 |
Financial journalist opinion
Based on 5 articles about SRTS published over the past 30 days
Negative
Zacks Investment Research
1 day ago
Sensus Healthcare, Inc. (SRTS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $7.10, marking a -1.53% move from the previous day.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Bulls Look Optimistic About Sensus Healthcare (SRTS): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 36.01%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in Sensus Healthcare (SRTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
2 weeks ago
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?
Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
2 weeks ago
Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration
Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 39.66% Upside in Sensus Healthcare (SRTS): Can the Stock Really Move This High?
The mean of analysts' price targets for Sensus Healthcare (SRTS) points to a 39.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
1 month ago
What Makes Sensus Healthcare (SRTS) a Good Fit for 'Trend Investing'
Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Neutral
GlobeNewsWire
1 month ago
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect.
Positive
Seeking Alpha
1 month ago
Sensus Healthcare: Q3 Results Showed That The Stock Is Undervalued
Sensus Healthcare's Q3 results exceeded expectations with 127% YoY revenue growth and EPS of $0.07, showcasing strong demand recovery and effective management strategies. The Fair Deal Agreement and new FDA contracts, including a major deal with Platinum Dermatology, promise recurring revenue and reduced client concentration risk. Despite impressive financial performance, the stock saw minimal movement, presenting a potential 150% upside over the next five years under my assumptions.
Neutral
Seeking Alpha
1 month ago
Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™